|
GB201317929D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
WO2015128653A2
(en)
|
2014-02-27 |
2015-09-03 |
Ucl Business Plc |
Ligand
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US11885806B2
(en)
|
2014-03-05 |
2024-01-30 |
Autolus Limited |
Method for depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA2945620C
(en)
*
|
2014-04-14 |
2022-12-06 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
WO2016120218A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向ｂ細胞成熟抗原之嵌合型抗原受體類
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507108D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
AU2016302881B2
(en)
|
2015-08-03 |
2022-09-15 |
Bristol-Myers Squibb Company |
Monoclonal antibodies against BCMA
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US11090334B2
(en)
|
2016-01-29 |
2021-08-17 |
Med Manor Organics (P) Ltd. |
Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
US10688104B2
(en)
|
2016-05-20 |
2020-06-23 |
Eli Lilly And Company |
Combination therapy with Notch and PD-1 or PD-L1 inhibitors
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR102512934B1
(ko)
*
|
2016-08-10 |
2023-03-23 |
레전드 바이오테크 아일랜드 리미티드 |
Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
EP3535295A1
(en)
|
2016-11-02 |
2019-09-11 |
EngMab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
AU2017357649A1
(en)
|
2016-11-11 |
2019-05-23 |
Autolus Limited |
Chimeric antigen receptor
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
JP7685735B2
(ja)
|
2016-12-02 |
2025-05-30 |
アンヘレス セラピューティクス インコーポレイテッド |
合成免疫受容体およびその使用方法
|
|
CA3048648A1
(en)
*
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
JP2020507605A
(ja)
*
|
2017-02-17 |
2020-03-12 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
|
|
GB201709508D0
(en)
*
|
2017-06-15 |
2017-08-02 |
Autolus Ltd |
Chimeric antigen receptor
|
|
US20210130775A1
(en)
*
|
2017-08-02 |
2021-05-06 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
GB201716728D0
(en)
|
2017-10-12 |
2017-11-29 |
Autolus Ltd |
Cell
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
EP3706754A1
(en)
|
2017-11-06 |
2020-09-16 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
CA3084445A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
WO2019140127A2
(en)
*
|
2018-01-10 |
2019-07-18 |
The General Hospital Corporation |
Immune cells expressing a chimeric antigen receptor
|
|
CN110709425B
(zh)
*
|
2018-02-01 |
2022-09-16 |
南京驯鹿医疗技术有限公司 |
一种结合bcma的嵌合抗原受体（car）及其应用
|
|
KR102943105B1
(ko)
*
|
2018-03-23 |
2026-03-24 |
가비쉬-가릴리 바이오 어플리케이션스 리미티드. |
막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg
|
|
GB201807693D0
(en)
|
2018-05-11 |
2018-06-27 |
Autolus Ltd |
Cell
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
FI3856775T3
(fi)
|
2018-09-27 |
2024-12-04 |
Autolus Ltd |
Kimeerinen antigeenireseptori
|
|
MX2021005022A
(es)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
US20220056407A1
(en)
|
2018-12-14 |
2022-02-24 |
Autolus Limited |
Cell
|
|
GB201904160D0
(en)
|
2019-03-26 |
2019-05-08 |
Autolus Ltd |
Cell
|
|
KR20210132668A
(ko)
*
|
2019-02-21 |
2021-11-04 |
아르벨 리미티드 |
인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
|
|
CN113543792A
(zh)
|
2019-03-08 |
2021-10-22 |
奥托路斯有限公司 |
包含工程化嵌合抗原受体和car调节剂的组合物和方法
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
SG11202109002XA
(en)
|
2019-03-21 |
2021-09-29 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
CN114127297A
(zh)
*
|
2019-03-26 |
2022-03-01 |
加维什-加利里生物应用有限公司 |
遗传重编程的表达car的treg
|
|
GB201904971D0
(en)
|
2019-04-08 |
2019-05-22 |
Autolus Ltd |
Cell
|
|
GB201906202D0
(en)
|
2019-05-02 |
2019-06-19 |
Autolus Ltd |
Cell
|
|
DK3967329T3
(da)
|
2019-05-07 |
2026-05-11 |
Gracell Bioscience Shanghai Co Ltd |
Genmanipuleret immuncelle, der er målrettet mod bcma, og anvendelse deraf
|
|
EP3964238A4
(en)
|
2019-05-07 |
2022-09-14 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
MANIPULATED IMMUNE CELL TARGETING BCMA AND USE THEREOF
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
CN110592015A
(zh)
*
|
2019-09-27 |
2019-12-20 |
中国科学院西双版纳热带植物园 |
一种诱导增强cik细胞的滇重楼多糖组合物及其应用
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
CN120051298A
(zh)
|
2022-08-05 |
2025-05-27 |
朱诺治疗学股份有限公司 |
Gprc5d和bcma特异性嵌合抗原受体
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
IL327045A
(en)
|
2023-10-05 |
2026-05-01 |
Capstan Therapeutics Inc |
Structure-restricted ionizable cationic lipids and lipid nanoparticles
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|